

a4
providing an antigen that comprises a common structural feature of IL-1 α and IL-1 β ;
exposing an antibody repertoire to the antigen; and
selecting from the repertoire an antibody that specifically binds IL-1 α and IL-1 β to
thereby obtain the dual specificity antibody, wherein said dual-specificity antibody is not
a fully mouse antibody.

a5
9. (Amended) The method of claim 4, wherein the antigen is made by splicing together
overlapping portions of IL-1 α and IL-1 β to create a hybrid molecule.

a6
31. (Amended) A dual-specificity antibody, or antigen-binding portion thereof, that
specifically binds interleukin-1 α and interleukin-1 β , said dual-specificity antibody, or
antigen-binding portion thereof obtainable by the method of claim 4.

Please add the following new claims 89-96 under the provisions of 37 CFR §1.121(c)(1)(I) so
they appear as follows:

- 89. (New) The dual-specificity antibody, or antigen-binding portion thereof according to
claim 1, wherein said dual-specificity antibody, or antigen-binding portion is fully
human.--

-- 90. (New) The dual-specificity antibody, or antigen-binding portion thereof according to
claim 1, wherein said dual-specificity antibody, or antigen-binding portion thereof, is
chimeric.--

a7
-- 91. (New) The dual-specificity antibody, or antigen binding portion thereof according to
claim 90, comprising mouse variable region amino acid sequences and human constant
region amino acid sequences.--

-- 92. (New) The dual-specificity antibody or antigen-binding portion thereof according to claim
1, wherein said dual-specificity antibody, or antigen-binding portion thereof, is CDR
grafted.—

- a7
- 93. (New) The dual-specificity antibody or antigen-binding portion thereof according to claim 92, comprising human heavy and light chain variable sequences containing one or more mouse CDRs.--
- 94. (New) The dual-specificity antibody or antigen-binding portion thereof according to claim 92, comprising mouse heavy and light chain variable sequences containing one or more human CDRs.--
- 95. (New) The dual-specificity antibody or antigen-binding portion thereof according to claim 1, wherein said dual-specificity antibody, or antigen-binding portion thereof, is humanized.--
- 